{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:22:18Z","timestamp":1790626938494,"version":"4.1.0"},"reference-count":133,"publisher":"Bentham Science Publishers Ltd.","issue":"1","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CGT"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:sec>\n<jats:title>Abstracts:<\/jats:title>\n<jats:p>Duchenne and Becker muscular dystrophies are allelic X-linked recessive neuromuscular\ndiseases affecting both skeletal and cardiac muscles. Therefore, owing to their single X chromosome,\nthe affected boys receive pathogenic gene mutations from their unknowing carrier mothers. Current\npharmacological drugs are palliative that address the symptoms of the disease rather than the genetic\ncause imbedded in the Dystrophin gene DNA sequence. Therefore, alternative therapies like gene\ndrugs that could address the genetic cause of the disease at its root are crucial, which include gene\ntransfer\/implantation, exon skipping, and gene editing. Presently, it is possible through genetic reprogramming\nto engineer AAV vectors to deliver certain therapeutic cargos specifically to muscle or other\norgans regardless of their serotype. Similarly, it is possible to direct the biogenesis of exosomes to\ncarry gene editing constituents or certain therapeutic cargos to specific tissue or cell type like brain\nand muscle. While autologous exosomes are immunologically inert, it is possible to camouflage AAV\ncapsids, and lipid nanoparticles to evade the immune system recognition. In this review, we highlight\ncurrent opportunities for Duchenne muscular dystrophy gene therapy, which has been known thus far\nas an incurable genetic disease. This article is a part of Gene Therapy of Rare Genetic Diseases thematic\nissue.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1566523223666221118160932","type":"journal-article","created":{"date-parts":[[2022,11,22]],"date-time":"2022-11-22T05:37:19Z","timestamp":1669095439000},"page":"17-28","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Duchenne Muscular Dystrophy Gene Therapy"],"prefix":"10.2174","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3170-3449","authenticated-orcid":true,"given":"Fawzy A.","family":"Saad","sequence":"first","affiliation":[{"name":"Department of Biology, Padua University School of Medicine, Via Trieste 75, Padova 35121, Italy"},{"name":"Department of\nGene Therapy, Saad Pharmaceuticals, Tornim\u00e4e 7-26, Tallinn, 10145, Estonia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasen F.","family":"Saad","sequence":"additional","affiliation":[{"name":"Department of\nGene Therapy, Saad Pharmaceuticals, Tornim\u00e4e 7-26, Tallinn, 10145, Estonia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Siciliano","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental\nMedicine, Pisa University School of Medicine, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciano","family":"Merlini","sequence":"additional","affiliation":[{"name":"Department of Biomedical and Neuromotor Sciences,\nBologna University School of Medicine, 40126 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9554-8794","authenticated-orcid":true,"given":"Corrado","family":"Angelini","sequence":"additional","affiliation":[{"name":"Department Neurosciences, Padova University\nSchool of Medicine, Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/0092-8674(87)90504-6","volume":"50","author":"Koenig M.","year":"1987","unstructured":"Koenig M.; Hoffman E.P.; Bertelson C.J.; Monaco A.P.; Feener C.; Kunkel L.M.; Complete cloning of the duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell 1987,50(3),509-517","journal-title":"Cell"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1016\/j.bbagrm.2017.08.010","volume":"1860","author":"Gherardi S.","year":"2017","unstructured":"Gherardi S.; Bovolenta M.; Passarelli C.; Transcriptional and epigenetic analyses of the DMD locus reveal novel cis acting DNA elements that govern muscle dystrophin expression. Biochim Biophys Acta Gene Regul Mech 2017,1860(11),1138-1147","journal-title":"Biochim Biophys Acta Gene Regul Mech"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"139","DOI":"10.3233\/JND-170218","volume":"4","author":"Young C.S.","year":"2017","unstructured":"Young C.S.; Mokhonova E.; Quinonez M.; Pyle A.D.; Spencer M.J.; Creation of a novel humanized dystrophic mouse model of duchenne muscular dystrophy and application of a CRISPR\/Cas9 gene editing therapy. J Neuromuscul Dis 2017,4(2),139-145","journal-title":"J Neuromuscul Dis"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/nyas.14231","volume":"1462","author":"Saad F.A.","year":"2020","unstructured":"Saad F.A.; Novel insights into the complex architecture of osteoporosis molecular genetics. Ann N Y Acad Sci 2020,1462(1),37-52","journal-title":"Ann N Y Acad Sci"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1002\/mus.21244","volume":"39","author":"Rodino-Klapac L.R.","year":"2009","unstructured":"Rodino-Klapac L.R.; Haidet A.M.; Kota J.; Handy C.; Kaspar B.K.; Mendell J.R.; Inhibition of myostatin with emphasis on follistatin as a therapy for muscle disease. Muscle Nerve 2009,39(3),283-296","journal-title":"Muscle Nerve"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1002\/humu.22758","volume":"36","author":"Bladen C.L.","year":"2015","unstructured":"Bladen C.L.; Salgado D.; Monges S.; The TREAT-NMD DMD Global Database: Analysis of more than 7,000 Duchenne muscular dystrophy mutations. Hum Mutat 2015,36(4),395-402","journal-title":"Hum Mutat"},{"key":"ref=7","first-page":"498","volume":"45","author":"Koenig M.","year":"1989","unstructured":"Koenig M.; Beggs A.H.; Moyer M.; The molecular basis for Duchenne versus Becker muscular dystrophy: Correlation of severity with type of deletion. Am J Hum Genet 1989,45(4),498-506","journal-title":"Am J Hum Genet"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1136\/jmg.28.12.860","volume":"28","author":"Love D.R.","year":"1991","unstructured":"Love D.R.; Flint T.J.; Genet S.A.; Middleton-Price H.R.; Davies K.E.; Becker muscular dystrophy patient with a large intragenic dystrophin deletion: Implications for functional minigenes and gene therapy. J Med Genet 1991,28(12),860-864","journal-title":"J Med Genet"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1002\/humu.20976","volume":"30","author":"Tuffery-Giraud S.","year":"2009","unstructured":"Tuffery-Giraud S.; B\u00e9roud C.; Leturcq F.; Genotype-phenotype analysis in 2,405 patients with a dystrophinopathy using the UMD-DMD database: A model of nationwide knowledgebase. Hum Mutat 2009,30(6),934-945","journal-title":"Hum Mutat"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1159\/000110334","volume":"12","author":"Mostacciuolo M.L.","year":"1993","unstructured":"Mostacciuolo M.L.; Miorin M.; Pegoraro E.; Reappraisal of the incidence rate of Duchenne and Becker muscular dystrophies on the basis of molecular diagnosis. Neuroepidemiology 1993,12(6),326-330","journal-title":"Neuroepidemiology"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/BF02272848","volume":"94","author":"Galvagni F.","year":"1994","unstructured":"Galvagni F.; Saad F.A.; Danieli G.A.; A study on duplications of the dystrophin gene: Evidence of a geographical difference in the distribution of breakpoints by intron. Hum Genet 1994,94(1),83-87","journal-title":"Hum Genet"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1073\/pnas.89.6.2331","volume":"89","author":"Roberts R.G.","year":"1992","unstructured":"Roberts R.G.; Bobrow M.; Bentley D.R.; Point mutations in the dystrophin gene. Proc Natl Acad Sci USA 1992,89(6),2331-2335","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/BF00220535","volume":"89","author":"Kilimann M.","year":"1992","unstructured":"Kilimann M.; Pizzuti A.; Grompe M.; Caskey C.T.; Point mutations and polymorphisms in the human dystrophin gene identified in genomic DNA sequences amplified by multiplex PCR. Hum Genet 1992,89(3),253-258","journal-title":"Hum Genet"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1093\/hmg\/1.5.345","volume":"1","author":"Saad F.A.","year":"1992","unstructured":"Saad F.A.; Vitiello L.; Merlini L.; Mostacciuolo M.L.; Oliviero S.; Danieli G.A.A.; 3\u2032 consensus splice mutation in the human dystrophin gene detected by a screening for intra-exonic deletions. Hum Mol Genet 1992,1(5),345-346","journal-title":"Hum Mol Genet"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1093\/hmg\/2.11.1877","volume":"2","author":"Lenk U.","year":"1993","unstructured":"Lenk U.; Hanke R.; Thiele H.; Speer A.; Point mutations at the carboxy terminus of the human dystrophin gene: Implications for an association with mental retardation in DMD patients. Hum Mol Genet 1993,2(11),1877-1881","journal-title":"Hum Mol Genet"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1093\/hmg\/2.3.311","volume":"2","author":"Prior T.W.","year":"1993","unstructured":"Prior T.W.; Papp A.C.; Snyder P.J.; Identification of two point mutations and a one base deletion in exon 19 of the dystrophin gene by heteroduplex formation. Hum Mol Genet 1993,2(3),311-313","journal-title":"Hum Mol Genet"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1002\/humu.1380020413","volume":"2","author":"Saad F.A.","year":"1993","unstructured":"Saad F.A.; Vita G.; Mora M.; A novel nonsense mutation in the human dystrophin gene. Hum Mutat 1993,2(4),314-316","journal-title":"Hum Mutat"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1002\/ajmg.1320460521","volume":"46","author":"Wilton S.D.","year":"1993","unstructured":"Wilton S.D.; Johnsen R.D.; Pedretti J.R.; Laing N.G.; Two distinct mutations in a single dystrophin gene: Identification of an altered splice-site as the primary becker muscular dystrophy mutation. Am J Med Genet 1993,46(5),563-569","journal-title":"Am J Med Genet"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/0960-8966(94)90069-8","volume":"4","author":"Saad F.A.","year":"1994","unstructured":"Saad F.A.; Vita G.; Toffolatti L.; Danieli G.A.; A possible missense mutation detected in the dystrophin gene by double strand conformation analysis (DSCA). Neuromuscul Disord 1994,4(4),335-341","journal-title":"Neuromuscul Disord"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1159\/000472188","volume":"4","author":"Tuffery S.","year":"1996","unstructured":"Tuffery S.; Bareil C.; Demaille J.; Claustres M.; Four novel dystrophin point mutations: Detection by protein truncation test and transcript analysis in lymphocytes from Duchenne muscular dystrophy patients. Eur J Hum Genet 1996,4(3),143-152","journal-title":"Eur J Hum Genet"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1002\/(SICI)1098-1004(1997)9:5<473:AID-HUMU16>3.0.CO;2-#","volume":"9","author":"Lasa A.","year":"1997","unstructured":"Lasa A.; Gallano P.; Baiget M.; Three novel point mutations in the dystrophin gene in DMD patients. Hum Mutat 1997,9(5),473-474","journal-title":"Hum Mutat"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1002\/(SICI)1098-1004(1997)9:2<188:AID-HUMU15>3.0.CO;2-Z","volume":"9","author":"Saad F.A.","year":"1997","unstructured":"Saad F.A.; Mostacciuolo M.L.; Trevisan C.P.; Novel mutations and polymorphisms in the human dystrophin gene detected by double-strand conformation analysis. Hum Mutat 1997,9(2),188-190","journal-title":"Hum Mutat"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1002\/(SICI)1098-1004(1997)10:3<217:AID-HUMU7>3.0.CO;2-F","volume":"10","author":"Sitnik R.","year":"1997","unstructured":"Sitnik R.; Campiotto S.; Vainzof M.; Novel point mutations in the dystrophin gene. Hum Mutat 1997,10(3),217-222","journal-title":"Hum Mutat"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1002\/(SICI)1098-1004(1998)12:1<70:AID-HUMU13>3.0.CO;2-G","volume":"12","author":"Cau M.","year":"1998","unstructured":"Cau M.; Cao A.; Loi D.; Two novel mutations (10410 T\u2192G; 10296 del C) at carboxy-terminus of the dystrophin gene associated with mental retardation. Hum Mutat 1998,12(1),70","journal-title":"Hum Mutat"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1002\/(SICI)1096-8628(19981102)80:2<99:AID-AJMG1>3.0.CO;2-L","volume":"80","author":"Saad F.A.","year":"1998","unstructured":"Saad F.A.; Merlini L.; Mostacciuolo M.L.; Danieli G.A.; Double missense mutation in exon 41 of the human dystrophin gene detected by double strand conformation analysis. Am J Med Genet 1998,80(2),99-102","journal-title":"Am J Med Genet"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1002\/(SICI)1098-1004(1999)13:2<170:AID-HUMU12>3.0.CO;2-7","volume":"13","author":"Ikezawa M.","year":"1999","unstructured":"Ikezawa M.; Nishino I.; Goto Y.; Miike T.; Nonaka I.; Newly recognized exons induced by a splicing abnormality from an intronic mutation of the dystrophin gene resulting in Duchenne muscular dystrophy. Hum Mutat 1999,13(2),170","journal-title":"Hum Mutat"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1007\/s004150070151","volume":"247","author":"Ginjaar H.B.","year":"2000","unstructured":"Ginjaar H.B.; van der Kooi A.J.; Ceelie H.; Sarcoglycanopathies in Dutch patients with autosomal recessive limb girdle muscular dystrophy. J Neurol 2000,247(7),524-529","journal-title":"J Neurol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1002\/pd.1238","volume":"25","author":"Percesepe A.","year":"2005","unstructured":"Percesepe A.; Ferrari M.; Coviello D.; Detection of a novel dystrophin gene mutation through carrier analysis performed during prenatal diagnosis in a case with intragenic recombination. Prenat Diagn 2005,25(11),1011-1014","journal-title":"Prenat Diagn"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.nmd.2008.11.003","volume":"19","author":"Baskin B.","year":"2009","unstructured":"Baskin B.; Banwell B.; Khater R.A.; Hawkins C.; Ray P.N.; Becker muscular dystrophy caused by an intronic mutation reducing the efficiency of the splice donor site of intron 26 of the dystrophin gene. Neuromuscul Disord 2009,19(3),189-192","journal-title":"Neuromuscul Disord"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.3892\/ijmm.2013.1498","volume":"32","author":"Zhu J.F.","year":"2013","unstructured":"Zhu J.F.; Liu H.H.; Zhou T.; Tian L.; Novel mutation in exon 56 of the dystrophin gene in a child with Duchenne muscular dystrophy. Int J Mol Med 2013,32(5),1166-1170","journal-title":"Int J Mol Med"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.nmd.2016.08.007","volume":"26","author":"Todeschini A.","year":"2016","unstructured":"Todeschini A.; Gualandi F.; Trabanelli C.; Becker muscular dystrophy due to an intronic splicing mutation inducing a dual dystrophin transcript. Neuromuscul Disord 2016,26(10),662-665","journal-title":"Neuromuscul Disord"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/15513815.2017.1369201","volume":"37","author":"Jiang J.","year":"2018","unstructured":"Jiang J.; Jiang T.; Xu J.; Shen J.; Gao F.; Novel mutation of the dystrophin gene in a child with duchenne muscular dystrophy. Fetal Pediatr Pathol 2018,37(1),1-6","journal-title":"Fetal Pediatr Pathol"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1186\/s12881-020-01157-0","volume":"21","author":"Wang Y.","year":"2020","unstructured":"Wang Y.; Chen Y.; Wang S.M.; Liu X.; Gu Y.N.; Feng Z.; Prenatal diagnosis of Duchenne muscular dystrophy revealed a novel mosaic mutation in Dystrophin gene: A case report. BMC Med Genet 2020,21(1),222","journal-title":"BMC Med Genet"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s13353-020-00605-0","volume":"62","author":"Zimowski J.G.","year":"2021","unstructured":"Zimowski J.G.; Purzycka J.; Pawelec M.; Ozdarska K.; Zaremba J.; Small mutations in Duchenne\/Becker muscular dystrophy in 164 unrelated Polish patients. J Appl Genet 2021,62(2),289-295","journal-title":"J Appl Genet"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/0888-7543(88)90113-9","volume":"2","author":"Monaco A.P.","year":"1988","unstructured":"Monaco A.P.; Bertelson C.J.; Liechti-Gallati S.; Moser H.; Kunkel L.M.; An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. Genomics 1988,2(1),90-95","journal-title":"Genomics"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.ymthe.2006.02.022","volume":"14","author":"Aartsma-Rus A.","year":"2006","unstructured":"Aartsma-Rus A.; Kaman W.E.; Weij R.; den Dunnen J.T.; van Ommen G.J.B.; van Deutekom J.C.T.; Exploring the frontiers of therapeutic exon skipping for Duchenne muscular dystrophy by double targeting within one or multiple exons. Mol Ther 2006,14(3),401-407","journal-title":"Mol Ther"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3390\/jpm8040041","volume":"8","author":"Echigoya Y.","year":"2018","unstructured":"Echigoya Y.; Lim K.R.Q.; Nakamura A.; Yokota T.; Multiple exon skipping in the duchenne muscular dystrophy hot spots: Prospects and challenges. J Pers Med 2018,8(4),41","journal-title":"J Pers Med"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1038\/nm1736","volume":"14","author":"Millay D.P.","year":"2008","unstructured":"Millay D.P.; Sargent M.A.; Osinska H.; Genetic and pharmacologic inhibition of mitochondrial-dependent necrosis attenuates muscular dystrophy. Nat Med 2008,14(4),442-447","journal-title":"Nat Med"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.nmd.2010.06.016","volume":"20","author":"Wissing E.R.","year":"2010","unstructured":"Wissing E.R.; Millay D.P.; Vuagniaux G.; Molkentin J.D.; Debio-025 is more effective than prednisone in reducing muscular pathology in mdx mice. Neuromuscul Disord 2010,20(11),753-760","journal-title":"Neuromuscul Disord"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.phrs.2017.09.001","volume":"125","author":"Schiavone M","year":"2017","unstructured":"Schiavone M; Zulian A; Menazza S; Alisporivir rescues defective mitochondrial respiration in Duchenne muscular dystrophy. Pharmacol Res 2017,125(Pt B),122-31","journal-title":"Pharmacol Res"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1002\/jcp.24290","volume":"228","author":"Pellegrini C.","year":"2013","unstructured":"Pellegrini C.; Zulian A.; Gualandi F.; Melanocytes-A novel tool to study mitochondrial dysfunction in Duchenne muscular dystrophy. J Cell Physiol 2013,228(6),1323-1331","journal-title":"J Cell Physiol"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"324","DOI":"10.3389\/fnagi.2014.00324","volume":"6","author":"Zulian A.","year":"2014","unstructured":"Zulian A.; Tagliavini F.; Rizzo E.; Melanocytes from patients affected by ullrich congenital muscular dystrophy and bethlem myopathy have dysfunctional mitochondria that can be rescued with cyclophilin inhibitors. Front Aging Neurosci 2014,6,324","journal-title":"Front Aging Neurosci"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1111\/j.1476-5381.2009.00316.x","volume":"157","author":"Tiepolo T.","year":"2009","unstructured":"Tiepolo T.; Angelin A.; Palma E.; The cyclophilin inhibitor Debio 025 normalizes mitochondrial function, muscle apoptosis and ultrastructural defects in Col6a1\u2212\/\u2212 myopathic mice. Br J Pharmacol 2009,157(6),1045-1052","journal-title":"Br J Pharmacol"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1073\/pnas.0610270104","volume":"104","author":"Angelin A.","year":"2007","unstructured":"Angelin A.; Tiepolo T.; Sabatelli P.; Mitochondrial dysfunction in the pathogenesis of Ullrich congenital muscular dystrophy and prospective therapy with cyclosporins. Proc Natl Acad Sci USA 2007,104(3),991-996","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.nmd.2014.03.009","volume":"24","author":"Merlini L.","year":"2014","unstructured":"Merlini L.; Nishino I.; 201st ENMC International Workshop: Autophagy in muscular dystrophies \u2013 Translational approach, 1\u20133 November 2013, Bussum, The Netherlands. Neuromuscul Disord 2014,24(6),546-561","journal-title":"Neuromuscul Disord"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"e109213","DOI":"10.1371\/journal.pone.0109213","volume":"9","author":"Cencic R.","year":"2014","unstructured":"Cencic R.; Miura H.; Malina A.; Protospacer adjacent motif (PAM)-distal sequences engage CRISPR Cas9 DNA target cleavage. PLoS One 2014,9(10),e109213","journal-title":"PLoS One"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.cell.2013.06.044","volume":"154","author":"Gilbert L.A.","year":"2013","unstructured":"Gilbert L.A.; Larson M.H.; Morsut L.; CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Cell 2013,154(2),442-451","journal-title":"Cell"},{"key":"ref=48","first-page":"1955.1964","volume":"475","author":"Eid A.","year":"1964","unstructured":"Eid A.; Alshareef S.; Mahfouz M.M.; CRISPR base editors: Genome editing without double-stranded breaks. Biochem J 1964,475(11),1955.1964","journal-title":"Biochem J"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s13059-018-1482-5","volume":"19","author":"Gapinske M.","year":"2018","unstructured":"Gapinske M.; Luu A.; Winter J.; CRISPR-SKIP: Programmable gene splicing with single base editors. Genome Biol 2018,19(1),107","journal-title":"Genome Biol"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/s41586-019-1711-4","volume":"576","author":"Anzalone A.V.","year":"2019","unstructured":"Anzalone A.V.; Randolph P.B.; Davis J.R.; Search-and-replace genome editing without double-strand breaks or donor DNA. Nature 2019,576(7785),149-157","journal-title":"Nature"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"5635","DOI":"10.1016\/j.cell.2021.09.018","volume":"184","author":"Chen P.J.","year":"2021","unstructured":"Chen P.J.; Hussmann J.A.; Yan J.; Enhanced prime editing systems by manipulating cellular determinants of editing outcomes. Cell 2021,184(22),5635-5652.e29","journal-title":"Cell"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.stemcr.2014.10.013","volume":"4","author":"Li H.L.","year":"2015","unstructured":"Li H.L.; Fujimoto N.; Sasakawa N.; Precise correction of the dystrophin gene in duchenne muscular dystrophy patient induced pluripotent stem cells by TALEN and CRISPR-Cas9. Stem Cell Reports 2015,4(1),143-154","journal-title":"Stem Cell Reports"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"6244","DOI":"10.1038\/ncomms7244","volume":"6","author":"Ousterout D.G.","year":"2015","unstructured":"Ousterout D.G.; Kabadi A.M.; Thakore P.I.; Majoros W.H.; Reddy T.E.; Gersbach C.A.; Multiplex CRISPR\/Cas9-based genome editing for correction of dystrophin mutations that cause Duchenne muscular dystrophy. Nat Commun 2015,6(1),6244","journal-title":"Nat Commun"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s13023-021-01758-9","volume":"16","author":"Kourakis S.","year":"2021","unstructured":"Kourakis S.; Timpani C.A.; Campelj D.G.; Standard of care versus new-wave corticosteroids in the treatment of Duchenne muscular dystrophy: Can we do better? Orphanet J Rare Dis 2021,16(1),117","journal-title":"Orphanet J Rare Dis"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1002\/mus.20812","volume":"36","author":"Angelini C.","year":"2007","unstructured":"Angelini C.; The role of corticosteroids in muscular dystrophy: A critical appraisal. Muscle Nerve 2007,36(4),424-435","journal-title":"Muscle Nerve"},{"key":"ref=56","first-page":"401","volume":"45","author":"Shah D.","year":"2008","unstructured":"Shah D.; Are corticosteroids effective in Duchenne muscular dystrophy. Indian Pediatr 2008,45(5),401-402","journal-title":"Indian Pediatr"},{"key":"ref=57","first-page":"CD003725","volume":"23","author":"Manzur A.Y.","year":"2008","unstructured":"Manzur A.Y.; Kuntzer T.; Pike M.; Swan A.; Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database Syst Rev 2008,23(1),CD003725","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"CD003725","DOI":"10.1002\/14651858.CD003725.pub4","volume":"2016","author":"Matthews E.","year":"2016","unstructured":"Matthews E.; Brassington R.; Kuntzer T.; Jichi F.; Manzur A.Y.; Corticosteroids for the treatment of Duchenne muscular dystrophy. Cochrane Libr 2016,2016(6),CD003725","journal-title":"Cochrane Libr"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1111\/dmcn.13590","volume":"60","author":"Schreiber A.","year":"2018","unstructured":"Schreiber A.; Brochard S.; Rippert P.; Corticosteroids in Duchenne muscular dystrophy: Impact on the motor function measure sensitivity to change and implications for clinical trials. Dev Med Child Neurol 2018,60(2),185-191","journal-title":"Dev Med Child Neurol"},{"key":"ref=60","author":"Buckon C","year":"2016","unstructured":"Buckon C; Sienko S; Bagley A; Can quantitative muscle strength and functional motor ability differentiate the influence of age and corticosteroids in ambulatory boys with duchenne muscular dystrophy? PLoS Curr 8. ecurrents.md.1ced64dff945f8958221fddcd4ee60b0.2016","journal-title":"PLoS Curr"},{"key":"ref=61","first-page":"200","volume":"39","author":"Merlini L.","year":"2020","unstructured":"Merlini L.; Cecconi I.; Parmeggiani A.; Cordelli D.M.; Dormi A.; Quadriceps muscle strength in Duchenne muscular dystrophy and effect of corticosteroid treatment. Acta Myol 2020,39(4),200-206","journal-title":"Acta Myol"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/S8756-3282(02)00687-7","volume":"30","author":"Pereira R.C.","year":"2002","unstructured":"Pereira R.C.; Delany A.M.; Canalis E.; Effects of cortisol and bone morphogenetic protein-2 on stromal cell differentiation: Correlation with CCAAT-enhancer binding protein expression. Bone 2002,30(5),685-691","journal-title":"Bone"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1172\/JCI2799","volume":"102","author":"Weinstein R.S.","year":"1998","unstructured":"Weinstein R.S.; Jilka R.L.; Parfitt A.M.; Manolagas S.C.; Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest 1998,102(2),274-282","journal-title":"J Clin Invest"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1210\/er.2012-1026","volume":"34","author":"Dallas S.L.","year":"2013","unstructured":"Dallas S.L.; Prideaux M.; Bonewald L.F.; The osteocyte: An endocrine cell... and more. Endocr Rev 2013,34(5),658-690","journal-title":"Endocr Rev"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"R131","DOI":"10.1530\/EJE-15-0118","volume":"173","author":"Mirza F.","year":"2015","unstructured":"Mirza F.; Canalis E.; Management of endocrine disease: Secondary osteoporosis: Pathophysiology and management. Eur J Endocrinol 2015,173(3),R131-R151","journal-title":"Eur J Endocrinol"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"4382","DOI":"10.1210\/endo.140.10.7034","volume":"140","author":"Hofbauer L.C.","year":"1999","unstructured":"Hofbauer L.C.; Gori F.; Riggs B.L.; Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: Potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology 1999,140(10),4382-4389","journal-title":"Endocrinology"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1359\/jbmr.2000.15.6.993","volume":"15","author":"Van Staa T.P.","year":"2000","unstructured":"Van Staa T.P.; Leufkens H.G.M.; Abenhaim L.; Zhang B.; Cooper C.; Use of oral corticosteroids and risk of fractures. J Bone Miner Res 2000,15(6),993-1000","journal-title":"J Bone Miner Res"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"e201800186","DOI":"10.26508\/lsa.201800186","volume":"2","author":"Heier C.R.","year":"2019","unstructured":"Heier C.R.; Yu Q.; Fiorillo A.A.; Vamorolone targets dual nuclear receptors to treat inflammation and dystrophic cardiomyopathy. Life Sci Alliance 2019,2(1),e201800186","journal-title":"Life Sci Alliance"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1002\/jcph.842","volume":"57","author":"Donovan J.M.","year":"2017","unstructured":"Donovan J.M.; Zimmer M.; Offman E.; Grant T.; Jirousek M.; A novel NF\u2010\u03baB inhibitor, Edasalonexent (CAT\u20101004), in development as a disease\u2010Modifying treatment for patients with duchenne muscular dystrophy: Phase 1 safety, pharmacokinetics, and pharmacodynamics in adult subjects. J Clin Pharmacol 2017,57(5),627-639","journal-title":"J Clin Pharmacol"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.nmd.2021.02.001","volume":"31","author":"Finkel R.S.","year":"2021","unstructured":"Finkel R.S.; Finanger E.; Vandenborne K.; Disease-modifying effects of edasalonexent, an NF-\u03baB inhibitor, in young boys with Duchenne muscular dystrophy: Results of the MoveDMD phase 2 and open label extension trial. Neuromuscul Disord 2021,31(5),385-396","journal-title":"Neuromuscul Disord"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.coph.2017.04.002","volume":"34","author":"Guiraud S.","year":"2017","unstructured":"Guiraud S.; Davies K.E.; Pharmacological advances for treatment in Duchenne muscular dystrophy. Curr Opin Pharmacol 2017,34,36-48","journal-title":"Curr Opin Pharmacol"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"eaay6812","DOI":"10.1126\/sciadv.aay6812","volume":"6","author":"Zhang Y.","year":"2020","unstructured":"Zhang Y.; Li H.; Min Y.L.; Enhanced CRISPR-Cas9 correction of Duchenne muscular dystrophy in mice by a self-complementary AAV delivery system. Sci Adv 2020,6(8),eaay6812","journal-title":"Sci Adv"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1038\/nbt.3469","volume":"34","author":"Yang Y.","year":"2016","unstructured":"Yang Y.; Wang L.; Bell P.; A dual AAV system enables the Cas9-mediated correction of a metabolic liver disease in newborn mice. Nat Biotechnol 2016,34(3),334-338","journal-title":"Nat Biotechnol"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"eabg4910","DOI":"10.1126\/sciadv.abg4910","volume":"7","author":"Chemello F.","year":"2021","unstructured":"Chemello F.; Chai A.C.; Li H.; Precise correction of Duchenne muscular dystrophy exon deletion mutations by base and prime editing. Sci Adv 2021,7(18),eabg4910","journal-title":"Sci Adv"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.12688\/f1000research.11243.1","volume":"6","author":"Lau C.H.","year":"2017","unstructured":"Lau C.H.; Suh Y.; In vivo genome editing in animals using AAV-CRISPR system: Applications to translational research of human disease. F1000 Res 2017,6,2153-2173","journal-title":"F1000 Res"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.braindev.2017.03.024","volume":"39","author":"Wang J.Z.","year":"2017","unstructured":"Wang J.Z.; Wu P.; Shi Z.M.; Xu Y.L.; Liu Z.J.; The AAV-mediated and RNA-guided CRISPR\/Cas9 system for gene therapy of DMD and BMD. Brain Dev 2017,39(7),547-556","journal-title":"Brain Dev"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","volume":"377","author":"Mendell J.R.","year":"2017","unstructured":"Mendell J.R.; Al-Zaidy S.; Shell R.; Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med 2017,377(18),1713-1722","journal-title":"N Engl J Med"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/0958-1669(93)90053-Y","volume":"4","author":"Cotten M.","year":"1993","unstructured":"Cotten M.; Wagner E.; Non-viral approaches to gene therapy. Curr Opin Biotechnol 1993,4(6),705-710","journal-title":"Curr Opin Biotechnol"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.bbadis.2006.07.009","volume":"1772","author":"Rando T.A.","year":"2007","unstructured":"Rando T.A.; Non-viral gene therapy for Duchenne muscular dystrophy: Progress and challenges. Biochim Biophys Acta Mol Basis Dis 2007,1772(2),263-271","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1093\/abbs\/gmp080","volume":"41","author":"Yang J.","year":"2009","unstructured":"Yang J.; Liu X.; Yu J.; A non-viral vector for potential DMD gene therapy study by targeting a minidystrophin-GFP fusion gene into the hrDNA locus. Acta Biochim Biophys Sin (Shanghai) 2009,41(12),1053-1060","journal-title":"Acta Biochim Biophys Sin (Shanghai)"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1093\/nar\/gkv1464","volume":"44","author":"Loperfido M.","year":"2016","unstructured":"Loperfido M.; Jarmin S.; Dastidar S.; piggyBac transposons expressing full-length human dystrophin enable genetic correction of dystrophic mesoangioblasts. Nucleic Acids Res 2016,44(2),744-760","journal-title":"Nucleic Acids Res"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1038\/mt.2015.192","volume":"24","author":"Xu L.","year":"2016","unstructured":"Xu L.; Park K.H.; Zhao L.; CRISPR-mediated genome editing restores dystrophin expression and function in mdx mice. Mol Ther 2016,24(3),564-569","journal-title":"Mol Ther"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/nbt.3081","volume":"33","author":"Zuris J.A.","year":"2015","unstructured":"Zuris J.A.; Thompson D.B.; Shu Y.; Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo. Nat Biotechnol 2015,33(1),73-80","journal-title":"Nat Biotechnol"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1038\/s41551-017-0137-2","volume":"1","author":"Lee K.","year":"2017","unstructured":"Lee K.; Conboy M.; Park H.M.; Nanoparticle delivery of Cas9 ribonucleoprotein and donor DNA in vivo induces homology-directed DNA repair. Nat Biomed Eng 2017,1(11),889-901","journal-title":"Nat Biomed Eng"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/humu.20918","volume":"30","author":"Aartsma-Rus A.","year":"2009","unstructured":"Aartsma-Rus A.; Fokkema I.; Verschuuren J.; Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations. Hum Mutat 2009,30(3),293-299","journal-title":"Hum Mutat"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/978-1-4939-8651-4_17","volume":"1828","author":"Mizobe Y.","year":"2018","unstructured":"Mizobe Y.; Miyatake S.; Takizawa H.; In vivo Evaluation of single-exon and multiexon skipping in mdx52 mice. Methods Mol Biol 2018,1828,275-292","journal-title":"Methods Mol Biol"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1146\/annurev-med-081117-010451","volume":"70","author":"Min Y.L.","year":"2019","unstructured":"Min Y.L.; Bassel-Duby R.; Olson E.N.; CRISPR correction of duchenne muscular dystrophy. Annu Rev Med 2019,70(1),239-255","journal-title":"Annu Rev Med"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"eaan8081","DOI":"10.1126\/scitranslmed.aan8081","volume":"9","author":"Amoasii L.","year":"2017","unstructured":"Amoasii L.; Long C.; Li H.; Single-cut genome editing restores dystrophin expression in a new mouse model of muscular dystrophy. Sci Transl Med 2017,9(418),eaan8081","journal-title":"Sci Transl Med"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1126\/science.aau1549","volume":"362","author":"Amoasii L.","year":"2018","unstructured":"Amoasii L.; Hildyard J.C.W.; Li H.; Gene editing restores dystrophin expression in a canine model of Duchenne muscular dystrophy. Science 2018,362(6410),86-91","journal-title":"Science"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1038\/mt.2010.123","volume":"18","author":"Incitti T.","year":"2010","unstructured":"Incitti T.; De Angelis F.G.; Cazzella V.; Exon skipping and duchenne muscular dystrophy therapy: Selection of the most active U1 snRNA antisense able to induce dystrophin exon 51 skipping. Mol Ther 2010,18(9),1675-1682","journal-title":"Mol Ther"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1038\/mt.2011.248","volume":"20","author":"Cirak S.","year":"2012","unstructured":"Cirak S.; Feng L.; Anthony K.; Restoration of the dystrophin-associated glycoprotein complex after exon skipping therapy in Duchenne muscular dystrophy. Mol Ther 2012,20(2),462-467","journal-title":"Mol Ther"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"S383","DOI":"10.3233\/JND-210696","volume":"8","author":"Novak J.S.","year":"2021","unstructured":"Novak J.S.; Spathis R.; Dang U.J.; Interrogation of dystrophin and dystroglycan complex protein turnover after exon skipping therapy. J Neuromuscul Dis 2021,8(s2),S383-S402","journal-title":"J Neuromuscul Dis"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1002\/humu.21114","volume":"30","author":"Flanigan K.M.","year":"2009","unstructured":"Flanigan K.M.; Dunn D.M.; von Niederhausern A.; Mutational spectrum of DMD mutations in dystrophinopathy patients: Application of modern diagnostic techniques to a large cohort. Hum Mutat 2009,30(12),1657-1666","journal-title":"Hum Mutat"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/1755-8794-4-36","volume":"4","author":"Kemaladewi D.U.","year":"2011","unstructured":"Kemaladewi D.U.; Hoogaars W.M.H.; van Heiningen S.H.; Dual exon skipping in myostatin and dystrophin for Duchenne muscular dystrophy. BMC Med Genomics 2011,4(1),36","journal-title":"BMC Med Genomics"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"e62","DOI":"10.1038\/mtna.2012.54","volume":"1","author":"Malerba A.","year":"2012","unstructured":"Malerba A.; Kang J.K.; McClorey G.; Dual myostatin and dystrophin exon skipping by morpholino nucleic acid oligomers conjugated to a cell-penetrating peptide is a promising therapeutic strategy for the treatment of duchenne muscular dystrophy. Mol Ther Nucleic Acids 2012,1(12),e62","journal-title":"Mol Ther Nucleic Acids"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2013\/402369","volume":"2013","author":"Aoki Y.","year":"2013","unstructured":"Aoki Y.; Yokota T.; Wood M.J.A.; Development of multiexon skipping antisense oligonucleotide therapy for Duchenne muscular dystrophy. BioMed Res Int 2013,2013,1-8","journal-title":"BioMed Res Int"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1002\/humu.20428","volume":"28","author":"B\u00e9roud C.","year":"2007","unstructured":"B\u00e9roud C.; Tuffery-Giraud S.; Matsuo M.; Multiexon skipping leading to an artificial DMD protein lacking amino acids from exons 45 through 55 could rescue up to 63% of patients with Duchenne muscular dystrophy. Hum Mutat 2007,28(2),196-202","journal-title":"Hum Mutat"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1159\/000008089","volume":"42","author":"Yazaki M.","year":"1999","unstructured":"Yazaki M.; Yoshida K.; Nakamura A.; Clinical characteristics of aged Becker muscular dystrophy patients with onset after 30 years. Eur Neurol 1999,42(3),145-149","journal-title":"Eur Neurol"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.jocn.2006.12.012","volume":"15","author":"Nakamura A.","year":"2008","unstructured":"Nakamura A.; Yoshida K.; Fukushima K.; Follow-up of three patients with a large in-frame deletion of exons 45-55 in the Duchenne muscular dystrophy (DMD) gene. J Clin Neurosci 2008,15(7),757-763","journal-title":"J Clin Neurosci"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/jhg.2016.152","volume":"62","author":"Nakamura A.","year":"2017","unstructured":"Nakamura A.; Shiba N.; Miyazaki D.; Comparison of the phenotypes of patients harboring in-frame deletions starting at exon 45 in the Duchenne muscular dystrophy gene indicates potential for the development of exon skipping therapy. J Hum Genet 2017,62(4),459-463","journal-title":"J Hum Genet"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1212\/WNL.44.12.2388","volume":"44","author":"Heald A.","year":"1994","unstructured":"Heald A.; Anderson L.V.B.; Bushby K.M.D.; Shaw P.J.; Becker muscular dystrophy with onset after 60 years. Neurology 1994,44(12),2388-2390","journal-title":"Neurology"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1002\/mus.21193","volume":"39","author":"Ferreiro V.","year":"2009","unstructured":"Ferreiro V.; Giliberto F.; Mu\u00f1iz G.M.N.; Asymptomatic Becker muscular dystrophy in a family with a multiexon deletion. Muscle Nerve 2009,39(2),239-243","journal-title":"Muscle Nerve"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"3547","DOI":"10.1093\/brain\/awr291","volume":"134","author":"Anthony K.","year":"2011","unstructured":"Anthony K.; Cirak S.; Torelli S.; Dystrophin quantification and clinical correlations in Becker muscular dystrophy: Implications for clinical trials. Brain 2011,134(12),3547-3559","journal-title":"Brain"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1136\/jnnp-2012-304729","volume":"85","author":"van den Bergen J.C.","year":"2014","unstructured":"van den Bergen J.C.; Schade van Westrum S.M.; Dekker L.; Clinical characterisation of Becker muscular dystrophy patients predicts favourable outcome in exon-skipping therapy. J Neurol Neurosurg Psychiatry 2014,85(1),92-98","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=105","first-page":"9","volume":"34","author":"Taglia A.","year":"2015","unstructured":"Taglia A.; Petillo R.; D\u2019Ambrosio P.; Clinical features of patients with dystrophinopathy sharing the 45-55 exon deletion of DMD gene. Acta Myol 2015,34(1),9-13","journal-title":"Acta Myol"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/jhg.2016.28","volume":"61","author":"Nakamura A.","year":"2016","unstructured":"Nakamura A.; Fueki N.; Shiba N.; Deletion of exons 3\u22129 encompassing a mutational hot spot in the DMD gene presents an asymptomatic phenotype, indicating a target region for multiexon skipping therapy. J Hum Genet 2016,61(7),663-667","journal-title":"J Hum Genet"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"193","DOI":"10.3233\/JND-170225","volume":"5","author":"Mori-Yoshimura M.","year":"2018","unstructured":"Mori-Yoshimura M.; Mitsuhashi S.; Nakamura H.; Characteristics of japanese patients with becker muscular dystrophy and intermediate muscular dystrophy in a japanese national registry of muscular dystrophy (Remudy): Heterogeneity and clinical variation. J Neuromuscul Dis 2018,5(2),193-203","journal-title":"J Neuromuscul Dis"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.bbrc.2018.09.039","volume":"505","author":"Tanihata J.","year":"2018","unstructured":"Tanihata J.; Nagata T.; Ito N.; Truncated dystrophin ameliorates the dystrophic phenotype of mdx mice by reducing sarcolipin-mediated SERCA inhibition. Biochem Biophys Res Commun 2018,505(1),51-59","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"eaap9004","DOI":"10.1126\/sciadv.aap9004","volume":"4","author":"Long C.","year":"2018","unstructured":"Long C.; Li H.; Tiburcy M.; Correction of diverse muscular dystrophy mutations in human engineered heart muscle by single-site genome editing. Sci Adv 2018,4(1),eaap9004","journal-title":"Sci Adv"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1126\/science.1225829","volume":"337","author":"Jinek M.","year":"2012","unstructured":"Jinek M.; Chylinski K.; Fonfara I.; Hauer M.; Doudna J.A.; Charpentier E.; A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 2012,337(6096),816-821","journal-title":"Science"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1126\/science.1231143","volume":"339","author":"Cong L.","year":"2013","unstructured":"Cong L.; Ran F.A.; Cox D.; Multiplex genome engineering using CRISPR\/Cas systems. Science 2013,339(6121),819-823","journal-title":"Science"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1126\/science.1232033","volume":"339","author":"Mali P.","year":"2013","unstructured":"Mali P.; Yang L.; Esvelt K.M.; RNA-guided human genome engineering via Cas9. Science 2013,339(6121),823-826","journal-title":"Science"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/cr.2016.28","volume":"26","author":"Mendell J.R.","year":"2016","unstructured":"Mendell J.R.; Rodino-Klapac L.R.; Duchenne muscular dystrophy: CRISPR\/Cas9 treatment. Cell Res 2016,26(5),513-514","journal-title":"Cell Res"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.mehy.2017.11.009","volume":"110","author":"Hagan M.","year":"2018","unstructured":"Hagan M.; Ashraf M.; Kim I.; Weintraub N.L.; Tang Y.; Effective regeneration of dystrophic muscle using autologous iPSC-derived progenitors with CRISPR-Cas9 mediated precise correction. Med Hypotheses 2018,110,97-100","journal-title":"Med Hypotheses"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1126\/science.aad5725","volume":"351","author":"Long C.","year":"2016","unstructured":"Long C.; Amoasii L.; Mireault A.A.; Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy. Science 2016,351(6271),400-403","journal-title":"Science"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1126\/science.aad5143","volume":"351","author":"Nelson C.E.","year":"2016","unstructured":"Nelson C.E.; Hakim C.H.; Ousterout D.G.; In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy. Science 2016,351(6271),403-407","journal-title":"Science"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1126\/science.aad5177","volume":"351","author":"Tabebordbar M.","year":"2016","unstructured":"Tabebordbar M.; Zhu K.; Cheng J.K.W.; In vivo gene editing in dystrophic mouse muscle and muscle stem cells. Science 2016,351(6271),407-411","journal-title":"Science"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1038\/s41576-018-0059-1","volume":"19","author":"Rees H.A.","year":"2018","unstructured":"Rees H.A.; Liu D.R.; Base editing: Precision chemistry on the genome and transcriptome of living cells. Nat Rev Genet 2018,19(12),770-788","journal-title":"Nat Rev Genet"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1038\/s41587-020-0509-0","volume":"38","author":"Sakata R.C.","year":"2020","unstructured":"Sakata R.C.; Ishiguro S.; Mori H.; Base editors for simultaneous introduction of C-to-T and A-to-G mutations. Nat Biotechnol 2020,38(7),865-869","journal-title":"Nat Biotechnol"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1038\/nbt.4148","volume":"36","author":"Ryu S.M.","year":"2018","unstructured":"Ryu S.M.; Koo T.; Kim K.; Adenine base editing in mouse embryos and an adult mouse model of Duchenne muscular dystrophy. Nat Biotechnol 2018,36(6),536-539","journal-title":"Nat Biotechnol"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1001\/jama.2019.21827","volume":"323","author":"Hampton T.","year":"2020","unstructured":"Hampton T.; DNA prime editing: A new CRISPR-based method to correct most disease-causing mutations. JAMA 2020,323(5),405-406","journal-title":"JAMA"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1186\/s13059-021-02458-0","volume":"22","author":"Li Y.","year":"2021","unstructured":"Li Y.; Chen J.; Tsai S.Q.; Cheng Y.; Easy-Prime: A machine learning\u2013based prime editor design tool. Genome Biol 2021,22(1),235","journal-title":"Genome Biol"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/343180a0","volume":"343","author":"England S.B.","year":"1990","unstructured":"England S.B.; Nicholson L.V.B.; Johnson M.A.; Very mild muscular dystrophy associated with the deletion of 46% of dystrophin. Nature 1990,343(6254),180-182","journal-title":"Nature"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1093\/hmg\/4.8.1245","volume":"4","author":"Wells D.J.","year":"1995","unstructured":"Wells D.J.; Wells K.E.; Asante E.A.; Expression of human full-length and minidystrophin in transgenic mdx mice: Implications for gene therapy of Duchenne muscular dystrophy. Hum Mol Genet 1995,4(8),1245-1250","journal-title":"Hum Mol Genet"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1016\/S0960-8966(02)00078-0","volume":"12","author":"Scott J.M.","year":"2002","unstructured":"Scott J.M.; Li S.; Harper S.Q.; Viral vectors for gene transfer of micro-, mini-, or full-length dystrophin. Neuromuscul Disord 2002,12(Suppl. 1),S23-S29","journal-title":"Neuromuscul Disord"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1093\/hmg\/11.7.733","volume":"11","author":"Fabb S.A.","year":"2002","unstructured":"Fabb S.A.; Wells D.J.; Serpente P.; Dickson G.; Adeno-associated virus vector gene transfer and sarcolemmal expression of a 144 kDa micro-dystrophin effectively restores the dystrophin-associated protein complex and inhibits myofibre degeneration in nude\/mdx mice. Hum Mol Genet 2002,11(7),733-741","journal-title":"Hum Mol Genet"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1161\/01.CIR.0000089371.11664.27","volume":"108","author":"Yue Y.","year":"2003","unstructured":"Yue Y.; Li Z.; Harper S.Q.; Davisson R.L.; Chamberlain J.S.; Duan D.; Microdystrophin gene therapy of cardiomyopathy restores dystrophin-glycoprotein complex and improves sarcolemma integrity in the mdx mouse heart. Circulation 2003,108(13),1626-1632","journal-title":"Circulation"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1136\/bmj.2.363.541","volume":"2","year":"1867","unstructured":"Duchenne. The pathology of paralysis with muscular degeneration (paralysie myosclerotique), or paralysis with apparent hypertrophy. BMJ 1867,2(363),541-542","journal-title":"BMJ"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"e2004840117","DOI":"10.1073\/pnas.2004840117","volume":"118","author":"Olson E.N.","year":"2021","unstructured":"Olson E.N.; Toward the correction of muscular dystrophy by gene editing. Proc Natl Acad Sci USA 2021,118(22),e2004840117","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"257","DOI":"10.3390\/genes13020257","volume":"13","author":"Wilton-Clark H.","year":"2022","unstructured":"Wilton-Clark H.; Yokota T.; Antisense and gene therapy options for duchenne muscular dystrophy arising from mutations in the N-terminal hotspot. Genes (Basel) 2022,13(2),257","journal-title":"Genes (Basel)"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.omtm.2021.06.015","volume":"22","author":"Ilyinskii P.O.","year":"2021","unstructured":"Ilyinskii P.O.; Michaud A.M.; Rizzo G.L.; ImmTOR nanoparticles enhance AAV transgene expression after initial and repeat dosing in a mouse model of methylmalonic acidemia. Mol Ther Methods Clin Dev 2021,22,279-292","journal-title":"Mol Ther Methods Clin Dev"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1089\/hum.2009.182","volume":"21","author":"Boutin S.","year":"2010","unstructured":"Boutin S.; Monteilhet V.; Veron P.; Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: Implications for gene therapy using AAV vectors. Hum Gene Ther 2010,21(6),704-712","journal-title":"Hum Gene Ther"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/mt.2013.244","volume":"22","author":"Chicoine L.G.","year":"2014","unstructured":"Chicoine L.G.; Montgomery C.L.; Bremer W.G.; Plasmapheresis eliminates the negative impact of AAV antibodies on microdystrophin gene expression following vascular delivery. Mol Ther 2014,22(2),338-347","journal-title":"Mol Ther"}],"container-title":["Current Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1566523223666221118160932","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/211056\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1566523223666221118160932","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T12:49:03Z","timestamp":1704286143000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/211056\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":133,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1566523223666221118160932","relation":{},"ISSN":["1566-5232"],"issn-type":[{"value":"1566-5232","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-05-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-27","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}